What Indian wastewater obligations a Roche acquirer inherits on Day 1
When Roche acquires a pharmaceutical plant in India in 2026, the asset inherits Consent to Establish and Consent to Operate under the Water (Prevention and Control of Pollution) Act 1974, the 2024 draft CPCB pharmaceutical sector effluent limits under the Environment (Protection) Rules, state-level Zero Liquid Discharge notifications, and Common Effluent Treatment Plant obligations. Roche's corporate water standard, covering TOC verification, ozone oxidation for recalcitrant active pharmaceutical ingredients, and AMR Industry Alliance antibiotic-residue targets, is layered on top of those Indian obligations; it does not replace them.
The legal stack is concrete. Sections 25 and 26 of the Water Act 1974 require every discharging industry to hold a Consent to Establish (CTE) before construction or expansion and a Consent to Operate (CTO) for the operating life of the plant. Both consents are issued by the State Pollution Control Board of the state where the plant sits, so for Roche Products (India) Private Limited, registered at 146-B, 166A, 8th Floor, R City, LBS Marg, Ghatkopar West, Mumbai 400086 (Tracxn, 2026-03), the consenting authority is the Maharashtra Pollution Control Board (MPCB). The CTO is granted to a specific legal entity and is not inherited on share transfer; the new owner must apply afresh, normally within 90 days of acquisition, and cannot operate the plant without a valid CTO in the new name.
On top of the Water Act consents sits the 2024 draft CPCB pharmaceutical sector effluent limits, which tighten BOD, COD and TSS relative to the older 2017 generic industry limits and add antibiotic-residue parameters that are still under stakeholder consultation. If the plant generates API residues, spent solvents or used oil above the thresholds listed in Schedules I and II, the acquirer also inherits a Hazardous Waste authorisation under the Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016. Plants that discharge to a Common Effluent Treatment Plant carry an additional set of obligations: inlet quality limits, equalisation tank duty, and a financial share of CETP expansion or upgradation works. Finally, plants in Maharashtra, Haryana, Gujarat, Punjab and Rajasthan fall under state-level Zero Liquid Discharge notifications that prohibit treated effluent discharge to surface water or land for new and expansion units, with retrofit deadlines already running for many existing brownfield sites.
Mapping Roche's corporate water standard onto Indian consent conditions
Roche's global water standard, published under the company's biodiversity and water programme, sets three internal obligations that an Indian consent condition does not by itself deliver: a pre-discharge TOC check on every production wastewater stream, the use of ozone to remove non- or poorly degradable contaminants, and a stated policy of not discharging toxicologically significant metals such as cadmium or mercury, with documented emissions consisting mainly of zinc, copper and chromium washed from piping (Roche, 2026). Layered onto the Indian minimum, those obligations reshape the ETP design basis, not just the discharge consent.
Roche's pre-discharge TOC check is the first point of difference. Indian consent conditions set numeric limits for COD and BOD, both of which miss a fraction of the slowly biodegradable API fragments that pass through a conventional activated-sludge stage. A TOC-based purity verification closes that gap because it measures the total organic load irrespective of biological degradability, so it catches solvents, intermediates and API fragments that would otherwise slip through a BOD-only consent. For the ETP designer, this means the final polishing stage must target a TOC floor, not a BOD floor.
Roche's documented use of ozone to remove non- or poorly degradable contaminants maps directly onto the antibiotic-residue parameters in the 2024 draft CPCB pharma limits. Conventional biological treatment does not reliably remove many antibiotic residues; ozone or an equivalent advanced oxidation process does. Treating the AMR Industry Alliance antibiotic-residue targets as binding during ETP design, rather than as a future stretch goal, prevents a costly retrofit once the draft limits are notified in 2026.
Roche's heavy-metal position, no discharge of cadmium or mercury and emissions consisting mainly of Zn, Cu and Cr from piping wash-off, is broadly consistent with the Indian consent regime, but the consent conditions need explicit parameter-by-parameter tracking for zinc, copper and chromium because these are present in measurable quantities in any stainless-steel-piping plant. Roche's water-reuse hierarchy, where cleaning water is reused for the next cleaning cycle where it is safe to do so, supports the Indian ZLD push by reducing the absolute wastewater volume the ETP and crystalliser have to handle, which in turn reduces steam, electrical and capex demand on the tertiary block.
Parameter-by-parameter comparison: Indian GSR 394(E) draft limits vs Roche internal targets
The table below maps the 2024 draft CPCB pharmaceutical sector limits against a representative state SPCB limit (Maharashtra MPCB) and Roche's internal target derived from the S2 water policy and the AMR Industry Alliance predicted-no-effect-concentrations framework. Where the draft CPCB value is still in consultation, Roche's internal target is shown as the binding design number.
| Parameter | Unit | 2024 draft CPCB pharma limit | Maharashtra MPCB typical consent limit | Roche internal target |
|---|---|---|---|---|
| pH | - | 6.5–8.5 | 6.5–8.5 | 6.5–8.5 |
| BOD (3-day, 27°C) | mg/L | ≤ 30 | ≤ 100 (CETP inlet) / ≤ 30 (land) | ≤ 20 |
| COD | mg/L | ≤ 250 | ≤ 250 | ≤ 200 (TOC-based verification) |
| TSS | mg/L | ≤ 100 | ≤ 100 | ≤ 50 |
| Total Dissolved Solids | mg/L | ≤ 2,100 | ≤ 2,100 | ZLD-state recovery ≥ 90% |
| Total Nitrogen | mg/L | ≤ 50 | ≤ 50 | ≤ 30 |
| Total Phosphorus | mg/L | ≤ 5 | ≤ 5 | ≤ 2 |
| Chloride | mg/L | ≤ 1,000 | ≤ 1,000 | ZLD-state recovery ≥ 90% |
| Sulphate | mg/L | ≤ 1,000 | ≤ 1,000 | ≤ 1,000 |
| Zinc (Zn) | mg/L | ≤ 1.0 | ≤ 1.0 | ≤ 0.5 |
| Copper (Cu) | mg/L | ≤ 0.5 | ≤ 0.5 | ≤ 0.3 |
| Total Chromium (Cr) | mg/L | ≤ 0.2 | ≤ 0.2 | ≤ 0.1 |
| Cadmium (Cd) | mg/L | ≤ 0.05 | ≤ 0.05 | Below detection limit (≤ 0.01) |
| Mercury (Hg) | mg/L | ≤ 0.01 | ≤ 0.01 | Below detection limit (≤ 0.001) |
| Antibiotic residues (class) | µg/L | PNEC-based, in consultation | Not separately specified | AMR Industry Alliance PNEC targets, binding now |
| Specific API loading | µg/L | Per-API PNEC under consultation | Case-by-case consent condition | Site-specific PNEC, validated by quarterly third-party testing |
Three points deserve emphasis. First, for cadmium and mercury, Roche's stated position of no discharge means internal targets are set at or below the analytical detection limit of the lab method, not at the consent number. Second, for antibiotic residues, the AMR Industry Alliance predicted-no-effect-concentrations (PNEC) framework is the right reference because Indian draft limits are still in consultation and will be PNEC-derived when notified. Third, for TDS and chloride in ZLD-notified states, the relevant compliance metric is water-recovery rate (≥ 90% on the evaporator-condensate-crystalliser train) rather than a concentration number, because there is no surface-water discharge stream to apply a concentration limit to.
ETP retrofit playbook for a brownfield Indian pharma acquisition
Step 1, days 0 to 30: run a 30-day wastewater characterisation across at least three production campaigns, covering API manufacturing, formulation, and cleaning-in-place peaks. Composite and grab samples must capture batch peaks in COD, TOC, specific API load and antibiotic residues. This dataset drives the sizing of the equalisation tank, the biological stage hydraulic retention time, and the ozone dose. Without it, any retrofit design is guesswork.
Step 2, days 30 to 60: audit the existing ETP for hydraulic capacity, sludge handling, and tertiary capability. Most brownfield Indian pharma ETPs built before 2015 have an activated-sludge or sequential-batch-reactor secondary stage that can be retained, but they lack membrane polishing, ozone or AOP, and online instrumentation. An MBR membrane bioreactor for tertiary pharma effluent polishing is typically the lowest-capex path to a consistent low-TSS, low-COD secondary effluent that an ozone stage can finish to the TOC target. For primary clarification, the choice between a DAF unit and a conventional clarifier is driven by API-floc behaviour; the trade-off is laid out in a DAF vs clarifier selection for pharma primary treatment benchmark that translates directly to Indian influent conditions.
Step 3, days 60 to 90: add ozone or an equivalent advanced oxidation stage sized at 2 to 5 g O3 per g dissolved COD on the recalcitrant API fraction, which mirrors Roche's documented use of ozone to remove non- or poorly degradable contaminants. A skid-mounted ozone generator for API and antibiotic residue oxidation sized on the characterisation data will normally meet both the TOC floor and the AMR Industry Alliance PNEC targets in a single stage. A chlorine dioxide generator is the right choice for the final disinfection step on the reuse loop, where it has the additional benefit of breaking down some phenolic API residues that ozone misses.
Step 4, days 90 to 180: for plants in ZLD-notified states, add a multiple-effect evaporator with mechanical vapour recompression and a forced-circulation crystalliser. The evaporator condensate becomes the new discharge stream and must be designed to meet the consent conditions; the crystalliser reject is sent to a secured landfill or to a solid-waste authorised re-processor. For an order-of-magnitude capex sanity check, an industrial wastewater treatment cost benchmark for an Indian pharma plant of comparable size is a reasonable starting point before issuing the FEED enquiry.
Step 5: install online TOC, COD, conductivity and flow meters on the final outlet, and on the CETP inlet where the plant discharges to a CETP. Roche's pre-discharge TOC check is most usefully run as a continuous online measurement, not as a daily grab sample, because batch discharges from API manufacturing can swing TOC by an order of magnitude within an hour.
90-day post-acquisition compliance action list
Days 0 to 30: file the Form XIII CTO transfer application with the relevant SPCB (MPCB for Maharashtra, HSPCB for Haryana, GPCB for Gujarat, PPCB for Punjab, RSPCB for Rajasthan) within 90 days of share purchase. In parallel, file the Form 1 hazardous-waste authorisation transfer under the 2016 Rules. Engage a NABL-accredited third-party lab for the 30-day wastewater characterisation campaign and confirm the chain-of-custody protocol for API-specific testing.
Days 31 to 60: complete a written gap analysis comparing current effluent quality against (a) the existing consent conditions, (b) the 2024 draft CPCB pharma limits, and (c) Roche's internal targets. Commission the ETP retrofit engineering study with a clear brief: meet the strictest of the three, design for ZLD if the plant is in a notified state, and target AMR Industry Alliance PNECs for antibiotic residues now rather than after notification.
Days 61 to 90: submit the retrofit capital approval to the acquirer's investment committee, place orders for long-lead items (membrane modules, ozone generators, evaporator-crystalliser skids), and notify the SPCB in writing of the compliance-upgrade timeline. The scale of the asset justifies a meaningful compliance budget: Roche Products (India) Private Limited reported revenue above ₹1,000 Cr for FY25 with 284 employees as of 1 March 2026 (Tracxn, 2026), which frames the order of magnitude of capex a 2026 Indian acquisition should expect to underwrite for ETP upgrade alone.
Frequently Asked Questions
Does the CTO automatically transfer to a new owner in India?
No. The CTO is granted to a specific legal entity under Section 26 of the Water Act 1974. On a share purchase that changes the controlling entity, the acquirer must apply for consent transfer, normally within 90 days, and the plant cannot operate without a valid CTO in the new entity's name.
Are antibiotic-residue limits in Indian pharma effluent law yet?
The 2024 draft CPCB pharmaceutical sector limits add antibiotic-residue parameters to the existing effluent schedule, but the final notified values are still under stakeholder consultation. Final notification is expected in 2026. As an AMR Industry Alliance signatory, Roche is expected to meet the predicted-no-effect-concentrations framework now, regardless of the Indian notification timeline.
Does an Indian pharma plant have to be Zero Liquid Discharge?
Only if the plant is in a ZLD-notified state, sits in a critically polluted industrial cluster identified by the CPCB, or draws groundwater beyond the threshold set by the Central Ground Water Authority. Plants outside those triggers can discharge treated effluent to a CETP or to a surface water body after consent-compliant treatment, but consent conditions still apply.
Can the existing ETP at an acquired plant be reused?
Usually the biological stage and the sludge-handling system can be retained. A tertiary upgrade is typically required to meet Roche's TOC floor and the AMR Industry Alliance PNEC targets: an MBR or UF polishing stage, followed by ozone or AOP for the recalcitrant API and antibiotic fraction, followed by online TOC and conductivity verification on the final outlet. A brownfield retrofit of this scope normally takes 6 to 9 months from FEED to commissioning.